Léa Frantzen1, Jean-David Cohen2, Sonia Tropé3, Morgane Beck4, Audrey Munos5, Marie-Annick Sittler6, Rita Diebolt7, Isabelle Metzler7, Christelle Sordet6. 1. Rheumatology department, hôpital Emile-Muller, GHR Mulhouse Sud Alsace, 20, rue du Dr René-Laennec 68051 Mulhouse, France. Electronic address: Lea.frantzen@ghrmsa.fr. 2. Rheumatology department, hôpital Lapeyronie, centre hospitalier universitaire de Montpellier, 371, avenue du doyen Gaston-Giraud, 34295 Montpellier, France. 3. Association nationale de défense contre l'arthrite rhumatoïde, 160, avenue de Fes 34080 Montpellier, France. 4. OMEDIT agence régionale de santé Grand Est, 14, rue du Maréchal-Juin 67000 Strasbourg, France. 5. Institut des métiers et des technologies, 38, avenue Marcel-Dassault 37206 Tours, France. 6. Rheumatology department, hôpital de Hautepierre, hôpitaux universitaire de Strasbourg, 1 avenue Molière, 67098 Strasbourg, France. 7. Association France Spondylarthrite, Section Alsace, hôpital de Hautepierre, 1 avenue Molière, 67098 Strasbourg, France.
Abstract
OBJECTIVE: To assess the patients' information about biosimilars and to identify the patients' incentives and deterrents to concur with the use of biosimilars. METHODS: Nation-wide cross-sectional study assessing information and concerns about biosimilars of French patients treated for rheumatic inflammatory diseases, whether they were treated or not by a biological DMARD. The assessment was available online from March to July 2017. RESULTS: Among the 629 respondents, 43% knew what biosimilars were. The main sources of information were rheumatologists and patient associations. Among patients treated with a biosimilar, 44% were not informed before they received the treatment. The patients' concerns focused on the non-similar molecular structure (46%), efficacy (60%) and safety (57%) comparatively to the originator biologic. 15% of respondents would refuse to switch their biologic to its biosimilar. More than 50% of respondents would warily accept to switch medications and interrupt the treatment if in doubt. Being informed about biosimilars and a good understanding of the definition of biosimilars were characteristics associated with better adherence to biosimilars. The rheumatologist was considered the most influent source of information about biosimilars and was considered reliable when deciding to switch a biologic to its biosimilar. Patient were reluctant to substitution of the medications by pharmacists (2%). Medico-economical issues acted as an incentive and a deterrent to accept the switch of medication. CONCLUSION: Biosimilars are largely unknown to patients. Information seems to be instrumental in improving the patients' adherence to biosimilars and could help preserving the therapeutic relationship and avoiding a nocebo effect.
OBJECTIVE: To assess the patients' information about biosimilars and to identify the patients' incentives and deterrents to concur with the use of biosimilars. METHODS: Nation-wide cross-sectional study assessing information and concerns about biosimilars of French patients treated for rheumatic inflammatory diseases, whether they were treated or not by a biological DMARD. The assessment was available online from March to July 2017. RESULTS: Among the 629 respondents, 43% knew what biosimilars were. The main sources of information were rheumatologists and patient associations. Among patients treated with a biosimilar, 44% were not informed before they received the treatment. The patients' concerns focused on the non-similar molecular structure (46%), efficacy (60%) and safety (57%) comparatively to the originator biologic. 15% of respondents would refuse to switch their biologic to its biosimilar. More than 50% of respondents would warily accept to switch medications and interrupt the treatment if in doubt. Being informed about biosimilars and a good understanding of the definition of biosimilars were characteristics associated with better adherence to biosimilars. The rheumatologist was considered the most influent source of information about biosimilars and was considered reliable when deciding to switch a biologic to its biosimilar. Patient were reluctant to substitution of the medications by pharmacists (2%). Medico-economical issues acted as an incentive and a deterrent to accept the switch of medication. CONCLUSION: Biosimilars are largely unknown to patients. Information seems to be instrumental in improving the patients' adherence to biosimilars and could help preserving the therapeutic relationship and avoiding a nocebo effect.
Authors: Antoine Perpoil; Gael Grimandi; Stéphane Birklé; Jean-François Simonet; Anne Chiffoleau; François Bocquet Journal: Int J Environ Res Public Health Date: 2020-12-29 Impact factor: 3.390
Authors: Yoon-Kyoung Sung; Sun-Young Jung; Hyoungyoung Kim; Seongmi Choi; Seul Gi Im; Yu Sang Lee; Eun Jin Jang; Soo-Kyung Cho Journal: PLoS One Date: 2020-01-24 Impact factor: 3.240
Authors: Yannick Vandenplas; Liese Barbier; Steven Simoens; Philippe Van Wilder; Arnold G Vulto; Isabelle Huys Journal: Front Pharmacol Date: 2022-01-05 Impact factor: 5.810